Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Xiaomi Shares Jump on Europe EV Expansion Plan 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
France Targets Shein, Temu With Fast-Fashion Fees 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
CAMBRIDGE, Mass., March 12, 2018 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the Oppenheimer & Co. 28th Annual Healthcare Conference at 10:20 a.m. ET on March 20, 2018 in New York City.
To access the live webcast of Epizyme’s presentation, please visit the Events & Presentations page within the Investor section of the company’s website at www.epizyme.com. A replay of the webcast will be available on the Epizyme website for 60 days following the event.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Contacts
Media:
Cheya Pope, Epizyme, Inc.
[email protected]
(617) 229-7561
Investors:
Jason Fredette, Epizyme, Inc.
[email protected]
(617) 500-0623
